OrbiMed’s Travere Therapeutics TVTX Stock Holding History

OrbiMed’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.4M	Buy	+253,000	New	+$11.2M	0.27%	78
2023 Q3	–	Sell	-2,118,100	Closed	-$32.5M	–	141
2023 Q2	$32.5M	Buy	2,118,100 +373,800	+21%	+$6.8M	0.59%	56
2023 Q1	$39.2M	Buy	1,744,300 +491,170	+39%	+$10.4M	0.77%	43
2022 Q4	$26.4M	Hold	1,253,130	–	–	0.5%	59
2022 Q3	$30.9M	Buy	1,253,130 +480,930	+62%	+$12.4M	0.57%	57
2022 Q2	$18.7M	Buy	+772,200	New	+$19.4M	0.34%	65
2021 Q2	–	Sell	-528,100	Closed	-$13.2M	–	177
2021 Q1	$13.2M	Buy	+528,100	New	+$14.6M	0.12%	112

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's TVTX Position: Q2 2026 in Review

OrbiMed opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 253,000 shares worth $14.4M. The stake represents 0.27% of the portfolio and ranks #78 among its holdings. This is a return to the name: OrbiMed previously reported a position in TVTX as recently as Q2 2023.

OrbiMed first reported a position in TVTX in Q1 2021 and has held it in 7 quarters since. The position peaked at $39.2M in Q1 2023. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

OrbiMed held 253,000 shares of Travere Therapeutics worth $14.4M as of Q2 2026.
Travere Therapeutics was a new OrbiMed position in Q2 2026.
Travere Therapeutics made up 0.27% of OrbiMed's portfolio in Q2 2026, its #78 holding.
OrbiMed first reported a position in Travere Therapeutics in Q1 2021 and has held it in 7 quarters since.
OrbiMed's Travere Therapeutics position peaked at $39.2M in Q1 2023.
319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.